Mazyar Shadman, MD, MPH

home / authors / mazyar-shadman-md-mph

Articles

Patient Selection and Timing Considerations for CAR T Therapy

Patient Selection and Timing Considerations for CAR T Therapy

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
March 7th 2025

Experts discuss patient selection and timing considerations for chimeric antigen receptor T-cell (CAR T) therapy in treating relapsed/refractory large B-cell lymphoma.

Long-Term Efficacy and Real-World Outcomes With Liso-cel

Long-Term Efficacy and Real-World Outcomes With Liso-cel

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
March 7th 2025

Experts discuss long-term efficacy and real-world outcomes with liso-cel in treating relapsed/refractory large B-cell lymphoma.

Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
February 28th 2025

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.

Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
February 28th 2025

Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: March 9th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes